Comparison
DSIP vs. Survodutide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Research other
Metabolic
CAS no.
62568-57-4
2179963-22-7
Molecular weight
848.81 g/mol
4727 g/mol
Half-life
0.1 h
168 h
Sequence
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glumodifiziertes 29-Aminosäuren-Peptid mit FettsäureseitenketteMechanism of action
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Survodutide
Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
4
2
of which in humans
1
2
Effects recorded
3
3
Open conflicts
1
0
Documented adverse events
1
2